logo
logo
HomeAbout UsPlatformInsights

Clinical Trial Insights

AllClinical TrialRegulatoryMerger & AcquisitionsBlogs
Abivax Announces Positive Phase 3 Results for Obefazimod in Ulcerative ColitisClinical Trial Updates

Abivax Announces Positive Phase 3 Results for Obefazimod in Ulcerative Colitis

Abivax announced positive topline results from its Phase 3 ABTECT-1 and ABTECT-2 trials evaluating obefazimod, a first-in-class oral miR-124 enhancer,...

Disc Medicine to Present Phase 1b Data of DISC-0974 in CKD Patients with Anemia at ASN Kidney Week 2025Clinical Trial Updates

Disc Medicine to Present Phase 1b Data of DISC-0974 in CKD Patients with Anemia at ASN Kidney Week 2025

Disc Medicine will present data from its Phase 1b trial of DISC-0974 in patients with non-dialysis-dependent chronic kidney disease (NDD-CKD) and anem...

Avidicure to Present Preclinical Data on TROP2-Targeting Antibody at ASCO 2025Clinical Trial Updates

Avidicure to Present Preclinical Data on TROP2-Targeting Antibody at ASCO 2025

Avidicure announced it will present preclinical data at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The data highlights AVC...

EMD Serono Presents Oncology Data at ASCO 2025Clinical Trial Updates

EMD Serono Presents Oncology Data at ASCO 2025

EMD Serono announced the presentation of new oncology data at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. Key highlights in...

AlphaMedix Phase 2 Data Shows Potential in Gastroenteropancreatic Neuroendocrine TumorsClinical Trial Updates

AlphaMedix Phase 2 Data Shows Potential in Gastroenteropancreatic Neuroendocrine Tumors

AlphaMedix phase 2 study (ALPHAMEDIX-02) evaluating AlphaMedix (212Pb-DOTAMTATE) in patients with advanced gastroenteropancreatic neuroendocrine tumor...

Editas Medicine Announces EDIT-401 Oral Presentation at ESGCT Congress and Participation in Investor ConferencesClinical Trial Updates

Editas Medicine Announces EDIT-401 Oral Presentation at ESGCT Congress and Participation in Investor Conferences

Editas Medicine announced an oral presentation on EDIT-401, a CRISPR gene editing medicine for lowering LDL-cholesterol by upregulating LDLR, at the E...

Baxdrostat Shows Significant Blood Pressure Reduction in Phase III Hypertension TrialClinical Trial Updates

Baxdrostat Shows Significant Blood Pressure Reduction in Phase III Hypertension Trial

Positive results from the BaxHTN Phase III trial demonstrated that baxdrostat, a highly selective aldosterone synthase inhibitor, significantly reduce...

Endogenex Presents Positive 48-Week REGENT-1 Clinical Trial Results for Type 2 Diabetes TreatmentClinical Trial Updates

Endogenex Presents Positive 48-Week REGENT-1 Clinical Trial Results for Type 2 Diabetes Treatment

Endogenex announced positive 48-week results from its REGENT-1 clinical study at Digestive Disease Week 2025. The study evaluated the safety and effic...

4TEEN4 Announces Promising First-in-Human Data for Procizumab in Cardiogenic ShockClinical Trial Updates

4TEEN4 Announces Promising First-in-Human Data for Procizumab in Cardiogenic Shock

4TEEN4 Pharmaceuticals announced the publication of data in the European Journal of Heart Failure demonstrating the efficacy and safety of procizumab,...

Envoy Medical's Pivotal Trial for Acclaim® Cochlear Implant Shows Positive One-Month Follow-Up ResultsClinical Trial Updates

Envoy Medical's Pivotal Trial for Acclaim® Cochlear Implant Shows Positive One-Month Follow-Up Results

Envoy Medical announced positive one-month follow-up results from the first stage of its pivotal clinical trial for the fully implanted Acclaim® Cochl...

Bicara Therapeutics Announces Positive Interim Data for Ficerafusp Alfa in Head and Neck CancerClinical Trial Updates

Bicara Therapeutics Announces Positive Interim Data for Ficerafusp Alfa in Head and Neck Cancer

Bicara Therapeutics announced updated interim data from a Phase 1/1b clinical trial of ficerafusp alfa in combination with pembrolizumab for first-lin...

Exelixis Announces Positive Phase 3 Results for Zanzalintinib and Atezolizumab Combination in Metastatic Colorectal CancerClinical Trial Updates

Exelixis Announces Positive Phase 3 Results for Zanzalintinib and Atezolizumab Combination in Metastatic Colorectal Cancer

Exelixis announced detailed results from the Phase 3 STELLAR-303 trial evaluating zanzalintinib in combination with atezolizumab versus regorafenib in...

Alto Neuroscience Validates EEG Biomarker for Schizophrenia, Strengthening Phase 2 Trial of ALTO-101Clinical Trial Updates

Alto Neuroscience Validates EEG Biomarker for Schizophrenia, Strengthening Phase 2 Trial of ALTO-101

Alto Neuroscience announced positive results from an independent, prospective replication study validating theta-band inter-trial coherence (ITC) as a...

EyePoint Completes Enrollment of Pivotal Phase 3 Trials for DURAVYU™ in Wet AMDClinical Trial Updates

EyePoint Completes Enrollment of Pivotal Phase 3 Trials for DURAVYU™ in Wet AMD

EyePoint Pharmaceuticals announced the completion of enrollment for its Phase 3 LUCIA trial evaluating DURAVYU™ for wet age-related macular degenerati...

BioInvent Announces Positive Phase 1 Data for BI-1206 in Combination with Pembrolizumab in Solid TumorsClinical Trial Updates

BioInvent Announces Positive Phase 1 Data for BI-1206 in Combination with Pembrolizumab in Solid Tumors

BioInvent International AB announced positive Phase 1 data for its drug candidate BI-1206, used in combination with Merck's KEYTRUDA (pembrolizumab), ...

First-Ever Combined Implantation of MOTUS Device and TOPS™ System for Lumbar Spinal DegenerationClinical Trial Updates

First-Ever Combined Implantation of MOTUS Device and TOPS™ System for Lumbar Spinal Degeneration

Drs. Lanman and Ament performed the first known combined implantation of the MOTUS total joint replacement device and the TOPS™ System at adjacent lum...

Actuate Therapeutics Announces Positive Phase 2 Elraglusib Data in Metastatic Pancreatic CancerClinical Trial Updates

Actuate Therapeutics Announces Positive Phase 2 Elraglusib Data in Metastatic Pancreatic Cancer

Actuate Therapeutics announced positive topline Phase 2 data for elraglusib in combination with gemcitabine/nab-paclitaxel (GnP) in first-line metasta...

Fulcrum Therapeutics Announces Positive Phase 1b Results for Pociredir in Sickle Cell DiseaseClinical Trial Updates

Fulcrum Therapeutics Announces Positive Phase 1b Results for Pociredir in Sickle Cell Disease

Fulcrum Therapeutics reported positive results from the 12 mg dose cohort of its Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD). Th...

Boehringer Ingelheim to Present Early Clinical Data on SIRPα Inhibitors at ASCO 2025Clinical Trial Updates

Boehringer Ingelheim to Present Early Clinical Data on SIRPα Inhibitors at ASCO 2025

Boehringer Ingelheim will present data from two early-stage clinical trials investigating their SIRPα inhibitors, BI 765063 and BI 770371, at the 2025...

Gain Therapeutics Receives Approval for Phase 1b Dosing Extension of GT-02287 for Parkinson's DiseaseClinical Trial Updates

Gain Therapeutics Receives Approval for Phase 1b Dosing Extension of GT-02287 for Parkinson's Disease

Gain Therapeutics announced Australian approval to extend the Phase 1b clinical trial of its drug candidate, GT-02287, for Parkinson's disease by nine...

Anaptys Announces Positive Phase 2b Results for Rosnilimab in Rheumatoid ArthritisClinical Trial Updates

Anaptys Announces Positive Phase 2b Results for Rosnilimab in Rheumatoid Arthritis

AnaptysBio announced positive late-breaking data from its Phase 2b trial of rosnilimab in rheumatoid arthritis (RA). The study demonstrated deepening ...

GeneSight Test Shows Faster Remission and Response in Depression Treatment: Post-Hoc AnalysisClinical Trial Updates

GeneSight Test Shows Faster Remission and Response in Depression Treatment: Post-Hoc Analysis

Myriad Genetics announced a post-hoc analysis of the PRIME study, revealing that patients with Major Depressive Disorder (MDD) treated based on GeneSi...

Boehringer and Click Therapeutics present positive Phase III data for CT-155 in SchizophreniaClinical Trial Updates

Boehringer and Click Therapeutics present positive Phase III data for CT-155 in Schizophrenia

Boehringer Ingelheim and Click Therapeutics announced positive results from the Phase III CONVOKE study of CT-155, an investigational prescription dig...

Genmab to Present Late-Stage Oncology Data at ASCO 2025Clinical Trial Updates

Genmab to Present Late-Stage Oncology Data at ASCO 2025

Genmab announced it will present new data at the 2025 ASCO Annual Meeting, focusing on its late-stage oncology portfolio. Key highlights include the ...

AbCellera Announces Positive Preclinical Data for ABCL575, an Anti-OX40L Antibody for Atopic DermatitisClinical Trial Updates

AbCellera Announces Positive Preclinical Data for ABCL575, an Anti-OX40L Antibody for Atopic Dermatitis

AbCellera presented preclinical data on ABCL575, a half-life extended anti-OX40L monoclonal antibody for moderate-to-severe atopic dermatitis. The da...

Gilead and Kite Present New Cancer Data at ESMO 2025, Highlighting Trodelvy's Potential in Metastatic TNBCClinical Trial Updates

Gilead and Kite Present New Cancer Data at ESMO 2025, Highlighting Trodelvy's Potential in Metastatic TNBC

Gilead and Kite will present new data at the ESMO 2025 Congress, showcasing progress in cancer treatment. Key highlights include Phase 3 ASCENT-03 stu...

Bolt Biotherapeutics Updates on BDC-4182 and Extends Cash Runway into 2027Clinical Trial Updates

Bolt Biotherapeutics Updates on BDC-4182 and Extends Cash Runway into 2027

Bolt Biotherapeutics announced an update on its Phase 1 dose escalation study of BDC-4182, an ISAC targeting claudin 18.2 for cancer treatment. Initia...

Guardant Health to Present Liquid Biopsy Data at ASCO 2025Clinical Trial Updates

Guardant Health to Present Liquid Biopsy Data at ASCO 2025

Guardant Health announced that it and its collaborators will present data from over 19 studies at the 2025 ASCO Annual Meeting. These studies highlig...

Apnimed Presents Phase 3 Data for AD109 in Obstructive Sleep Apnea at CHEST 2025Clinical Trial Updates

Apnimed Presents Phase 3 Data for AD109 in Obstructive Sleep Apnea at CHEST 2025

Apnimed announced additional data from its Phase 3 SynAIRgy and LunAIRo trials evaluating AD109 (aroxybutynin 2.5 mg/atomoxetine 75 mg) for obstructiv...

Harmony Biosciences Presents Preclinical Data for BP1.15205, a Potential Best-in-Class OX2R Agonist for NarcolepsyClinical Trial Updates

Harmony Biosciences Presents Preclinical Data for BP1.15205, a Potential Best-in-Class OX2R Agonist for Narcolepsy

Harmony Biosciences announced positive preclinical data for BP1.15205, a novel orexin 2 receptor (OX2R) agonist, demonstrating significant wake-promot...

Breath Diagnostics' OneBreath™ Technology Predicts Pneumonia Onset Through Exhaled Breath AnalysisClinical Trial Updates

Breath Diagnostics' OneBreath™ Technology Predicts Pneumonia Onset Through Exhaled Breath Analysis

Breath Diagnostics announced results from a peer-reviewed clinical study published in The Journal of Thoracic and Cardiovascular Surgery, demonstratin...

Hengrui and Kailera Present Clinical Data for HRS9531 and HRS-7535 at ADA 2025Clinical Trial Updates

Hengrui and Kailera Present Clinical Data for HRS9531 and HRS-7535 at ADA 2025

Jiangsu Hengrui Pharmaceuticals and Kailera Therapeutics announced the presentation of six abstracts at the American Diabetes Association's 85th Scien...

Adagene Announces Positive Updated Data for Muzastotug (ADG126) in Combination with Pembrolizumab for Colorectal Cancer at ASCOClinical Trial Updates

Adagene Announces Positive Updated Data for Muzastotug (ADG126) in Combination with Pembrolizumab for Colorectal Cancer at ASCO

Adagene announced updated Phase 1b/2 data for its anti-CTLA-4 antibody, Muzastotug (ADG126), in combination with pembrolizumab, in patients with micro...

BriaCell's Phase 2 Trial Shows Promising Survival Rates in Metastatic Breast CancerClinical Trial Updates

BriaCell's Phase 2 Trial Shows Promising Survival Rates in Metastatic Breast Cancer

BriaCell Therapeutics Corp. announced updated survival data from its Phase 2 clinical study of Bria-IMT in patients with metastatic breast cancer (MBC...

4B Technologies Announces Positive Phase 1 Results for Novel Non-Opioid Chronic Pain TherapyClinical Trial Updates

4B Technologies Announces Positive Phase 1 Results for Novel Non-Opioid Chronic Pain Therapy

4B Technologies announced positive topline results from a Phase 1 study of 4B03-04, a humanized monoclonal antibody for chronic pain. The trial demon...

AB Science Announces Initial Phase 1 Data for AB8939 and Venetoclax Combination in Refractory or Relapsed Acute Myeloid LeukemiaClinical Trial Updates

AB Science Announces Initial Phase 1 Data for AB8939 and Venetoclax Combination in Refractory or Relapsed Acute Myeloid Leukemia

AB Science SA announced initial Phase 1 data for the combination of AB8939 with venetoclax for treating refractory or relapsed acute myeloid leukemia ...

AbbVie Announces Positive Phase 3 Results for Upadacitinib (RINVOQ®) in VitiligoClinical Trial Updates

AbbVie Announces Positive Phase 3 Results for Upadacitinib (RINVOQ®) in Vitiligo

AbbVie announced positive topline results from two replicate Phase 3 studies evaluating upadacitinib (RINVOQ®) in adult and adolescent patients with n...

Aicuris' Pritelivir Meets Primary Endpoint in Phase 3 Trial for Refractory Herpes Simplex Virus in Immunocompromised PatientsClinical Trial Updates

Aicuris' Pritelivir Meets Primary Endpoint in Phase 3 Trial for Refractory Herpes Simplex Virus in Immunocompromised Patients

Aicuris Anti-infective Cures AG announced positive results from its Phase 3 trial (PRIOH-1) of pritelivir for treating refractory Herpes Simplex Virus...

Ascentage Pharma's Lisaftoclax Shows Promise in Venetoclax-Refractory Patients; ASCO 2025 PresentationClinical Trial Updates

Ascentage Pharma's Lisaftoclax Shows Promise in Venetoclax-Refractory Patients; ASCO 2025 Presentation

Ascentage Pharma announced positive clinical data for lisaftoclax, a Bcl-2 inhibitor, and alrizomadlin, an MDM2-p53 inhibitor. Data from a Phase 1b/2...

Candel Therapeutics to Present CAN-2409 Data at SITC 2025Clinical Trial Updates

Candel Therapeutics to Present CAN-2409 Data at SITC 2025

Candel Therapeutics will present data from its enLIGHTEN™ Discovery Platform and CAN-2409 program in non-small cell lung cancer (NSCLC) at the SITC 20...

← PrevPage 3 of 8Next →

Get a Demo of the Enterprise AI & Knowledge Platform

Private by design. Speaks your language. Proven at scale

Book a Demo